As of November 6, 2026, Viridian Therapeutics, Inc. is a publicly traded company (Nasdaq: VRDN). The largest holder reporting an active stake on Schedule 13D is Fairmount Funds Management LLC, at 14.04%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Bellevue Group AG (6.6%), Paradigm BioCapital Advisors LP (6.1%), Kynam Capital Management, LP (5.7%) (Schedule 13D/A, May 13, 2026).
Is this your company?
About to sign with, pay or invest in Viridian Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Viridian Therapeutics, Inc. a real, registered company?
- Viridian Therapeutics, Inc. files with the SEC under CIK 1590750 (its SEC filings).
- Its shares are listed under the ticker VRDN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Viridian Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Point72 (filed 2026-08-20).
Who are Viridian Therapeutics, Inc.'s owners and officers?
Viridian Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-20).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-20 | Point72 Asset Management, L.P. | 5% |
| Schedule 13G/A, 2026-08-14 | Paradigm Biocapital Advisors LP | 6.1% |
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 5.2% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 3.25% |
| Schedule 13G/A, 2026-08-14 | Kynam Capital Management, LP | 5.7% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.5% |
| Schedule 13G, 2026-06-26 | Paradigm Biocapital Advisors LP | 5.1% |
| Schedule 13G, 2026-05-15 | Bellevue Group Ag | 6.6% |
| Schedule 13D/A, 2026-05-13 | Fairmount Funds Management LLC | 14.04% |
| Schedule 13G, 2026-05-08 | Deep Track Capital, LP | 5.3% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Kynam Capital Management, LP | 1.54% |
Questions about who owns Viridian Therapeutics, Inc.
Who owns Viridian Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Viridian Therapeutics, Inc.: Fairmount Funds Management LLC (14.04%, Schedule 13D/A, filed 2026-05-13), Bellevue Group Ag (6.6%, Schedule 13G, filed 2026-05-15), Paradigm Biocapital Advisors LP (6.1%, Schedule 13G/A, filed 2026-08-14), Kynam Capital Management, LP (5.7%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07); 2 more are listed above.
Who are the largest shareholders of Viridian Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Viridian Therapeutics, Inc. on this page are Fairmount Funds Management LLC (14.04%), Bellevue Group Ag (6.6%) and Paradigm Biocapital Advisors LP (6.1%).
When did Fairmount Funds Management LLC buy into Viridian Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2026-05-13, reporting 14.04%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Viridian Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Viridian Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Viridian Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Viridian Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Fairmount Healthcare Fund II L.P., a director and 10% owner: 5,090,928 shares (4.5% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-05-13).
- Fairmount Healthcare Fund II GP LLC, a director and 10% owner: 5,090,928 shares (4.5% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-05-13).
- Fairmount Funds Management LLC, a director and 10% owner: 5,090,928 shares (4.5% of shares outstanding), held indirectly through By Fairmount Healthcare Fund II L.P., on a joint filing (Form 4, 2026-05-13).
- , the chief medical officer: 40,000 shares (0.04% of shares outstanding) (Form 4, 2026-08-18).
- , the chief executive and president: 33,349 shares (0.03% of shares outstanding) (Form 4/A, 2026-03-09).
Shares outstanding: 113,558,449 as of 2026-11-02, from the company's latest SEC cover page.
How much has Viridian Therapeutics, Inc. raised?
No fundraising or offering filing from Viridian Therapeutics, Inc. is on file with us.
Keep reading
More on Viridian Therapeutics, Inc. and the records around it.
Viridian Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/viridian-therapeutics